Drugplain

Carnitor 1 g/10mL

levocarnitine · SOLUTION · Leadiant Biosciences, Inc.

4 Recalls on Record
Plain English

Carnitor is a prescription carnitine supplement used to treat carnitine deficiency, a condition where the body lacks sufficient carnitine needed for energy production in cells. It comes as an oral solution and works by replacing the carnitine that the body cannot produce or absorb adequately on its own.

Key Facts

Brand Name
Carnitor
Generic Name
levocarnitine
NDC Code (Product)
54482-145
Manufacturer
Leadiant Biosciences, Inc.
Strength
1 g/10mL
Dosage Form
SOLUTION
Route
ORAL
Marketing Status
Application #
NDA019257
Drug Class
Carnitine Analog [EPC]
Marketing Start
04/10/1986

Recall History

4 Recalls on Record
Class II05/28/2015

Lincare, Inc.

Lack of Assurance of Sterility: Sterility of product is not assured.

TerminatedVoluntary: Firm initiated
Class II05/28/2015

Lincare, Inc.

Lack of Assurance of Sterility: Sterility of product is not assured.

TerminatedVoluntary: Firm initiated
Class II05/28/2015

Lincare, Inc.

Lack of Assurance of Sterility: Sterility of product is not assured.

TerminatedVoluntary: Firm initiated
Class II05/28/2015

Lincare, Inc.

Lack of Assurance of Sterility: Sterility of product is not assured.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

seizure375 reports
off label use274 reports
vomiting221 reports
diarrhoea199 reports
drug ineffective190 reports
fatigue177 reports
pneumonia176 reports
pyrexia167 reports
product dose omission issue131 reports
nausea129 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.

Dosage & Administration

DOSAGE AND ADMINISTRATION CARNITOR ® (levocarnitine) Tablets. Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response. Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response. Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition. CARNITOR ® (levocarnitine) Oral Solution and CARNITOR ® SF (levocarnitine) Sugar-Free Oral Solution. For oral use only. Not for parenteral use. Adults: The recommended dosage of levocarnitine is 1 to 3 g/day for a 50 kg subject, which is equivalent to 10 to 30 mL/day of CARNITOR ® (levocarnitine) Oral Solution or CARNITOR ® SF (levocarnitine) Sugar-Free Oral Solution. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit. Dosage should start at 1 g/day, (10 mL/day), and be increased slowly while assessing tole

Warnings

WARNINGS Hypersensitivity Reactions Serious hypersensitivity reactions, including rash, urticaria, and facial edema have been reported with oral CARNITOR ® . Other serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following intravenous levocarnitine administration, mostly in patients with end stage renal disease undergoing dialysis. Discontinue use of CARNITOR ® and instruct patients to seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.

Contraindications

CONTRAINDICATIONS None known.

Drug Interactions

Drug Interactions Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.

Adverse Reactions

ADVERSE REACTIONS The following adverse reactions associated with the use of oral formulations of levocarnitine were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliability, or to establish a causal relationship to drug exposure. Gastrointestinal Reactions : Various mild gastrointestinal complaints have been reported during the long-term administration of oral L- or D,L-carnitine; these include transient nausea and vomiting, abdominal cramps, and diarrhea. Gastrointestinal adverse reactions with CARNITOR ® (levocarnitine) Oral Solution or CARNITOR ® SF (levocarnitine) Sugar-Free Oral Solution dissolved in liquids might be avoided by a slow consumption of the solution or by a greater dilution. Decreasing the dosage often diminishes or eliminates drug-related patient body odor or gastrointestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration, and after any dosage increases. Musculoskeletal Reactions : Mild myasthenia has been described only in uremic patients receiving D,L-

Frequently Asked Questions

What is Carnitor used for?

Carnitor is a prescription carnitine supplement used to treat carnitine deficiency, a condition where the body lacks sufficient carnitine needed for energy production in cells. It comes as an oral solution and works by replacing the carnitine that the body cannot produce or absorb adequately on its own.

Is Carnitor a controlled substance?

Carnitor is not classified as a controlled substance by the DEA.

What is the generic name for Carnitor?

The generic name for Carnitor is levocarnitine. There are 10 other brand versions of levocarnitine.

What is the NDC code for Carnitor 1 g/10mL?

The NDC (National Drug Code) for Carnitor 1 g/10mL is 54482-145, listed by Leadiant Biosciences, Inc..